Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE) Financial Performance & Income Statement Overview
Review Ultragenyx Pharmaceutical Inc. (RARE) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Ultragenyx Pharmaceutical Inc. (RARE) Income Statement & Financial Overview
Review Ultragenyx Pharmaceutical Inc. RARE income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $139.29M | $164.88M | $139.49M | $147.03M |
| Cost of Revenue | $28.66M | $16.89M | $21.02M | $30.14M |
| Gross Profit | $110.63M | $147.98M | $118.47M | $116.88M |
| Gross Profit Ratio | $0.79 | $0.90 | $0.85 | $0.79 |
| R&D Expenses | $165.77M | $187.77M | $170.11M | $152.64M |
| SG&A Expenses | $87.80M | $82.50M | $80.35M | $80.60M |
| Operating Expenses | $253.57M | $270.26M | $250.46M | $233.25M |
| Total Costs & Expenses | $282.23M | $287.15M | $271.48M | $263.39M |
| Interest Income | $6.83M | $9.55M | $10.73M | $7.40M |
| Interest Expense | $14.34M | $15.52M | $15.71M | $15.96M |
| Depreciation & Amortization | $8.99M | $9.08M | $8.76M | $8.86M |
| EBITDA | -$126.44M | -$108.80M | -$108.74M | -$105.92M |
| EBITDA Ratio | -$0.91 | -$0.66 | -$0.78 | -$0.72 |
| Operating Income | -$142.94M | -$122.28M | -$131.99M | -$116.36M |
| Operating Income Ratio | -$1.03 | -$0.74 | -$0.95 | -$0.79 |
| Other Income/Expenses (Net) | -$6.83M | -$11.13M | -$1.23M | -$14.38M |
| Income Before Tax | -$149.77M | -$133.40M | -$133.21M | -$130.74M |
| Income Before Tax Ratio | -$1.08 | -$0.81 | -$0.95 | -$0.89 |
| Income Tax Expense | $1.31M | -$19000.00 | $303000.00 | $858000.00 |
| Net Income | -$151.08M | -$133.38M | -$133.52M | -$131.60M |
| Net Income Ratio | -$1.08 | -$0.81 | -$0.96 | -$0.90 |
| EPS | -$1.57 | -$1.39 | -$1.40 | -$1.52 |
| Diluted EPS | -$1.57 | -$1.39 | -$1.40 | -$1.52 |
| Weighted Avg Shares Outstanding | $96.29M | $95.68M | $95.49M | $86.58M |
| Weighted Avg Shares Outstanding (Diluted) | $96.29M | $95.68M | $95.49M | $86.58M |
The company's financials show resilient growth, with revenue advancing from $147.03M in Q2 2024 to $139.29M in Q1 2025. Gross profit remained healthy with margins at 79% in Q1 2025 compared to 79% in Q2 2024. Operating income hit -$142.94M last quarter, sustaining a consistent -103% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$126.44M. Net income dropped to -$151.08M, while earnings per share reached -$1.57. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan